Artrya Limited · ASX:AYA
Artrya — Shareholder Meeting (November 2025)
22 slides from Artrya's shareholder meeting presentation, Nov 13, 2025
Slide 1: Coronary Artery Disease. We see you. 2025 Chair's AGM Address
Coronary Artery Disease. We see you. 2025 CHAIR'S ANNUAL GENERAL MEETING ADDRESS AND PRESENTATION PERTH, Australia, 13 November 2025: Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix AI-powered cloud platform, for the near real time, point of
Slide 2: Chair's Address to the Annual General Meeting of Shareholders
Chair's Address to the Annual General Meeting of Shareholders Good morning, ladies and gentlemen – thank you for joining us today, whether that be in person or virtually and welcome to Artrya’s Annual General Meeting for the 2025 financial year. Some of the highlights for FY2025 are: • Continued dev
Slide 3: Chair's address: thanks and acknowledgements
I would like to take this opportunity to thank my fellow Board Directors and the Artrya executive team for their dedication and contribution throughout FY25. I also extend my sincere appreciation to our long-term shareholders for their continued support and trust, and I warmly welcome our new shareh
Slide 4: 2025 Annual General Meeting CEO Presentation
(ASX: AYA) For personal use only 2025 Annual General Meeting [ CEO Presentation Advancing Commercialisation Reshaping the Future of [ Heart Care I Artrya 2025 AGM Presentation
Slide 5: Important Notice and Disclaimer
Important Notice The Presentation Materials contain summary information about the Company and its activities which is current as at the IMPORTANT NOTICE AND DISCLAIMER date of the Presentation Materials. The information in the Presentation Materials is of a general nature and does not These presenta
Slide 6: FY25 Key Achievements
FY25 Key Achievements FY25 built the foundation; FY26 marks commercial scale-up. FY2025 FY2026 YTD For personal use only Foundation Year Execution & Growth FDA status FDA clearance for Salix® Coronary Anatomy FDA clearance for Salix® Coronary Plaque U.S. commercial launch with Tanner Health – 5-year
Slide 7: Large market opportunity and defined path to revenue
Large market opportunity and defined path to revenue For personal use only High value global opportunity Established commercial momentum Defined market entry Best-in-class AI solution $4.4B1 U.S. addressable FDA-cleared Salix® Accelerate revenue growth Go-to-market strategy for coronary artery marke
Slide 8: Salix is unique in providing real-time patient assessment
Salix® is unique in providing real-time patient assessment Real-time clinical insights for coronary artery disease from a single AI-driven solution Point of care enabling real-time – without humans For personal use only Plaque analysis from CCTA scans in under 10 mins without human intervention Deta
Slide 9: Salix is a single platform solution built to scale
Salix® is a single platform solution built to scale Modular software powering complete, scalable CCTA analysis for coronary artery disease. Increasing clinical utility & For personal use only revenue opportunity Salix® Coronary Flow Module Final validation stage – Expected FDA clearance 1Q 2026 US$1
Slide 10: Seamlessly fits into the clinical workflow
Seamlessly fits into the clinical workflow Salix® integrates effortlessly into existing systems; simple to deploy, use, and update. Onsite - Manual Assessment For personal use only Review & Report Prepare Clinician Receives Report Current Approach Offsite – ‘Human in the loop’ Review, Prepare & Repo
Slide 11: Salix live demonstration
For personal use only Salix® live demonstration I Artrya 2025 AGM Presentation
Slide 12: Strong value proposition for all stakeholders
Strong value proposition for all stakeholders Salix® transforms accuracy, efficiency, and patient outcomes across the healthcare ecosystem. For personal use only Patients Clinicians Health Systems Integrated workflow that accelerates Benefit from faster results and reporting and streamlines clinicia
Slide 13: Go to Market strategy
For personal use only Go to Market strategy Commercial pathway for 2026 and beyond
Slide 14: From strategy to scale: executing with precision
From strategy to scale: executing with precision Delivering focused execution through three clear go-to-market strategies For personal use only 01 02 03 Foundation Customers SAPPHIRE Study Key Opinion Leaders Partner with early adopters to Conduct a targeted clinical study Mobilise influential clini
Slide 15: 2026 goals: establishing a scalable U.S. operation
2026 goals: establishing a scalable U.S. operation Building the foundation for sustainable commercial growth through revenue, clinical validation, and operational readiness. For personal use only Drive Commercial Growth Clinical & operational excellence Build for scale & credibility Three foundation
Slide 16: Foundation customers: Salix live and expanding
Foundation customers: Salix® live and expanding Tanner Health is live on Salix today; Cone Health and Northeast Georgia Health System are the next U.S. launch partners. Currently Live Additional Revenue For personal use only Tanner Health System Next U.S. foundation customers • 5-year commercial agr
Slide 17: SAPPHIRE Study: Clinical innovation with commercial impact
SAPPHIRE Study: Clinical innovation with commercial impact SAPPHIRE is intended to change the way risk is assessed in CAD patients and build long-term partnerships with leading hospitals For personal use only Strategic partnerships Changing how CAD is Awareness & credibility assessed • Delivered wit
Slide 18: Building operational infrastructure for U.S. growth
Building operational infrastructure for U.S. growth Dedicated U.S. Support team across reimbursement, integration, clinical field support, and customer success. U.S. President Clinical Advisory Board For personal use only New leadership structure bringing U.S. healthcare Independent cardiovascular K
Slide 19: U.S. footprint across leading health systems
U.S. footprint across leading health systems Foundation customers, SAPPHIRE sites, and our Atlanta support pod working together to drive U.S. growth. Mass. General For personal use only Massachusetts 12 hospitals 32 Cardiology Centres Cone Health North Carolina 5 hospitals 24 Heart Centres Ascension
Slide 20: Keys to our commercial success
Keys to our commercial success Competitive advantage built on product strength, pricing flexibility, and customer experience For personal use only Product – Superior 01 We deliver a superior product to hospital systems and clinicians, combining real-time assessment with integrated workflows and a us
Slide 21: Summary & Outlook
Summary & Outlook Salix® has moved from R&D to commercial use, with growing revenues and a structured pathway for U.S. expansion. 1 Commercialisation activities and platform now scaling. For personal use only 2 The U.S. market is large and growing, with established reimbursement codes. 3 Salix® is l
Slide 22: Contact details
For personal use only www.artrya.com Corporate Enquiries Investor & Media Enquiries John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artr